Novartis Clozapine Anti-Generic Study Has Not Persuaded State Formularies
Executive Summary
Novartis' presentations of recent study data questioning the interchangeability of its antipsychotic Clozaril and Zenith's generic clozapine have not persuaded any states to restrict generic substitution of the drugs.
You may also be interested in...
Zenith-Goldline Clozapine Bioequivalence Study Suggested By FDA
FDA is recommending Zenith-Goldline conduct a bioequivalence study on generic clozapine based on concerns raised by journal publications about the safety and efficacy of its version of the schizophrenia drug.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011